Insiders Rigel Pharmaceuticals, Inc.

Equities

RIGL

US7665596034

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
1.02 ^USD	+2.79%		-11.30%	-29.66%

05-07	Transcript : Rigel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07	Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer	03-12	CI
Athersys Names Jane Wasman as Board Chair	02/10/23	MT
Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics	06/06/23	CI
Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023	03/02/23	CI
Insider Buy: Rigel Pharmaceuticals	13/06/22	MT
Rigel Pharmaceuticals, Inc. Appoints Kamil Ali-Jackson to Board of Directors	16/12/21	CI
Rigel Pharmaceuticals, Inc. Appoints Alison L. Hannah, M.D. to Its Board of Directors	14/05/21	CI
Rigel Pharmaceuticals, Inc. Announces Resignation of Nelson D. Cabatuan as Vice President, Finance and Principal Accounting Officer, Effective on October 16, 2020	08/10/20	CI
Rigel Pharmaceuticals, Inc. Appoints Dave Santos as Executive Vice President and Chief Commercial Officer	04/08/20	CI
Eldon C. Mayer Informes Rigel Pharmaceuticals, Inc. to Resign as the Company’s Chief Commercial Officer, Effective as of December 23, 2019	17/12/19	CI
Rigel Pharmaceuticals, Inc. Names Wolfgang Dummer as Chief Medical Officer	23/10/19	CI
Rigel Pharmaceuticals, Inc. Announces Resignation of Anne-Marie Duliege, Executive Vice President and Chief Medical Officer, Effective August 31, 2019	16/05/19	CI
Peter S. Ringrose Announces Not to Stand for Re-Election to Board of Rigel Pharmaceuticals, Inc	09/04/19	CI
Rigel Pharmaceuticals, Inc. Announces Board Changes	26/03/19	CI
Rigel Pharmaceuticals, Inc. Appoints Dean Schorno as Executive Vice President and Chief Financial Officer	30/05/18	CI
Rigel Pharmaceuticals Announces Executive Changes	15/12/17	CI
Rigel Pharmaceuticals, Inc. Appoints Gregg A. Lapointe to the Board of Directors and Audit Committee	03/11/17	CI
Rigel Pharmaceuticals, Inc. Appoints Brian L. Kotzin to Its Board of Directors	25/08/17	CI
Rigel Pharmaceuticals, Inc. Announces New Hires	01/08/17	CI
Rigel Pharmaceuticals Receives Approval from Food and Drug Administration for Tavalisse as Proprietary Name for Fostamatinib in the United States	27/04/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Rigel Pharmaceuticals, Inc.

Equities

RIGL

US7665596034

Insiders

Filters